Postoperative radiation therapy for primary vs. recurrent squamous cell carcinoma of the head and neck: Results of a comparative analysis

Head & Neck ◽  
1999 ◽  
Vol 21 (6) ◽  
pp. 554-559 ◽  
Author(s):  
William F. Regine ◽  
Joseph Valentino ◽  
David A. Sloan ◽  
Pushpa Patel ◽  
Melissa Q. Pittard ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Radiation Therapy ◽  
Comparative Analysis ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Postoperative Radiation ◽  
Postoperative Radiation Therapy ◽  
Recurrent Squamous Cell Carcinoma

Postoperative radiation therapy for squamous cell carcinoma of the head and neck

2003 ◽  
Vol 24 (1) ◽  
pp. 41-50 ◽  
Author(s):  
William M. Mendenhall ◽  
Robert J. Amdur ◽  
Russell W. Hinerman ◽  
Douglas B. Villaret ◽  
Dietmar W. Siemann
Keyword(s):  
Squamous Cell Carcinoma ◽  
Radiation Therapy ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Postoperative Radiation ◽  
Postoperative Radiation Therapy

Adjuvant chemotherapy for high-risk squamous-cell carcinoma of the head and neck.

1987 ◽  
Vol 5 (3) ◽  
pp. 456-458 ◽  
Author(s):  
J T Johnson ◽  
E N Myers ◽  
V L Schramm ◽  
D G Mayernik ◽  
T A Nolan ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Radiation Therapy ◽  
Adjuvant Chemotherapy ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Advanced Squamous Cell Carcinoma ◽  
Postoperative Radiation ◽  
Postoperative Radiation Therapy ◽  
Study Support

A prospective clinical trial was developed to evaluate efficacy, toxicity, and patient compliance to adjuvant chemotherapy following surgery and postoperative radiation therapy in patients with squamous-cell carcinoma of the head and neck with extracapsular spread of tumor in cervical metastases. Following postoperative radiation therapy, 18 courses of methotrexate (MTX) and 5-fluorouracil (5-FU) were administered over 6 months. Fifty patients were registered. A total of 771 doses were administered. Dose reduction was required 72 times. Therapy was stopped in one patient (2%) because of toxicity. Three patients (6%) refused to complete the adjuvant therapy. Adjusted 2-year no evidence of disease (NED) survival is 66%. This study demonstrates that patients with advanced squamous-cell carcinoma of the head and neck can undertake an aggressive program of adjuvant MTX/5-FU with acceptable compliance and toxicities. Preliminary data generated in this nonrandomized study support the call for a prospective randomized multiinstitutional trial of this program.

Sign in / Sign up

Export Citation Format

Share Document